115017-00-0 Usage
General Description
(-)-Profenamine, also known as clobenzorex, is a sympathomimetic amine used as an anorectic drug in the treatment of obesity. It stimulates the central nervous system and increases the release of norepinephrine, leading to a decrease in appetite and an increase in energy expenditure. (-)-Profenamine is structurally related to amphetamine and has similar effects on the body, including increased heart rate and blood pressure. It is commonly used as a short-term treatment for weight loss, but its long-term safety and efficacy have not been well-established. Side effects of (-)-Profenamine may include insomnia, irritability, and potential for abuse or dependence. It is important to use (-)-Profenamine only under the supervision of a doctor and in combination with a healthy diet and exercise.
Check Digit Verification of cas no
The CAS Registry Mumber 115017-00-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,0,1 and 7 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 115017-00:
(8*1)+(7*1)+(6*5)+(5*0)+(4*1)+(3*7)+(2*0)+(1*0)=70
70 % 10 = 0
So 115017-00-0 is a valid CAS Registry Number.
115017-00-0Relevant articles and documents
CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME
-
Page 30, (2010/02/06)
Pharmaceutical preparations adapted for mucosal delivery, preferably for nasal delivery, which can be easily and safely used over days to weeks with minimal side effects. The pharmaceutical preparations comprise microcapsules comprising at least one pharmaceutically active agent. The microcapsules provide controlled release of the pharmaceutically active agent. Cytotoxicity is avoided for cytotoxic pharmaceutically active agents and/or for cytotoxic dosages by one or more of the following: (a) manipulating the mucosal transport rate of the pharmaceutically active agent through the mucosal bodies to achieve a transport rate which is substantially the same as the controlled release rate, and/or (b) selecting only a most active and/or less cytotoxic enantiomer of the pharmaceutically active agent for use in the pharmaceutical preparation.
Stability of some phenothiazine free radicals.
Levy,Tozer,Tuck,Loveland
, p. 898 - 905 (2007/10/10)
-
